Fundraising Fox
/Companies
Sign in

Surrozen Inc./DE

NASDAQ: SRZN

South San Francisco, US · Founded 2021 · Delaware corporation

Find your way into Surrozen Inc./DE

Sign up to see every warm intro you have to Surrozen Inc./DE

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Surrozen Inc./DE team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Surrozen is a biotechnology company developing antibody-based therapeutics that activate the Wnt signaling pathway to promote tissue repair, with initial focus on ophthalmology indications including diabetic macular edema, wet age-related macular degeneration, and corneal endothelial disease.

Biotech

Founders & leadership

CP
Craig ParkerExecutive
CW
Charles WilliamsExecutive
YL
Yang Li, Ph.D.Named on SEC filing

Board

TK
Tim Kutzkey, Ph.D.Board director
AB
Anna Berkenblit, M.D.Board director
MH
Mary Haak-Frendscho, Ph.D.Board director
DJ
David J. Woodhouse, Ph.D.Board director
MR
Mace Rothenberg, M.D.Board director
SL
Shao-Lee Lin, M.D., Ph.D.Board director
CC
Christopher ChaiBoard director
EB
Eric BjerkholtBoard director

Reported raises · per SEC filings

Form D private placements

$269.4M disclosed across 2 rounds · 2024–2025

▶$76.4MraisedApr 2025 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yang Li, Ph.D.Executive Officer
  • Anna Berkenblit, M.D.Director
  • Mary Haak-Frendscho, Ph.D.Director
  • David J. Woodhouse, Ph.D.Director
  • Craig ParkerExecutive Officer, Director
  • Charles WilliamsExecutive Officer
  • Mace Rothenberg, M.D.Director
  • Shao-Lee Lin, M.D., Ph.D.Director
  • Tim Kutzkey, Ph.D.Director
  • Christopher ChaiDirector
  • Eric BjerkholtDirector
Offering amount
$175M
Amount sold
$76.4M
Sales commissions
$4.6M
Placement agents
Guggenheim Securities, LLC
First sale
Mar 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$193MraisedApr 2024 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mace Rothenberg, M.D.Director
  • Craig ParkerExecutive Officer, Director
  • Charles WilliamsExecutive Officer
  • David J. Woodhouse, Ph.D.Director
  • Anna Berkenblit, M.D.Director
  • Eric BjerkholtDirector
  • Christopher ChaiDirector
  • Mary Haak-Frendscho, Ph.D.Director
  • Tim Kutzkey, Ph.D.Director
  • Shao-Lee Lin, M.D., Ph.D.Director
Offering amount
$193M
Amount sold
$193M
Placement agents
Guggenheim Securities, LLC
First sale
Apr 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Surrozen Inc./DE do?
Surrozen is a biotechnology company developing antibody-based therapeutics that activate the Wnt signaling pathway to promote tissue repair, with initial focus on ophthalmology indications including diabetic macular edema, wet age-related macular degeneration, and corneal endothelial disease.
How much funding has Surrozen Inc./DE raised?
Surrozen Inc./DE has disclosed $269.4M raised across 2 rounds.
Where is Surrozen Inc./DE headquartered?
Surrozen Inc./DE is headquartered in South San Francisco, US.